Abstract 6079
Background
This study focuses on epidemiology of IFD before and after allo-HSCT in children and adults with Hodgkin’s lymphoma (HL).
Methods
Single center prospective observational study included 86 patients with classical r/r HL who received allo-HSCT from 2002 to 2018. The median age was 27 (13-49) y.o., children (<18 yo) – 13% (n = 11). Allo-HSCT from MUD was performed in 45,4% (n = 39), MRD – 24,4% (n = 21), MMUD – 15,1% (n = 13), haplo – 15,1% (n = 13), with RIC (100%) and predominantly PTCY-based GvHD prophylaxis (71%). Primary antifungal prophylaxis was flu in 85%, secondary – vori (100%). EORTC/MSG 2008 criteria for diagnosis and response to therapy were used. Median follow-up time was 12 months [1-71].
Results
Incidence of IFD before allo-HSCT was 12,8% (n = 11). Antifungal therapy before allo-HSCT was used in 81,8% pts with median duration – 2 months. Complete response to antifungal therapy was in 45,4% pts, partial response or stabilization – 36,4%, and 18,2% pts had an “active IFD”. Cumulative incidence of relapse or progression of IA after allo-HSCT was 18,2% with the median 49 day [19-79] after HSCT, which were successfully treated with vori in post HSCT period. Incidence of IFD after allo-HSCT for naïve patients was 17,6% (n = 13/74). Etiology of IFD after allo-HSCT was IA – 69%, invasive candidiasis – 15%, mucormycosis – 8% and 8% combined IFD caused by Asp. fumigatus + Rhizopus stolonifer. The median day of onset of IFD after allo-HSCT was day+ 114 [1-489]. Antifungal therapy was used in all patients: vori – 59%, mica– 17%, posa – 8%, L-AmB – 8% and combination L-AmB with caspo – 8%. Overall survival (OS) at 12 weeks from the diagnosis of IFD after allo-HSCT was 80%. The 2-year OS in children and adult with HL after allo-HSCT was 73,3%. Development of IFD after allo-HSCT do not decrease the 2-year OS rate (69,2% vs 74%, p = 0,77, figure 1a). The impact of prior IFD on 2-year OS in allo-HSCT recipients was not statistically significant in all group (63,6% vs 74,7%, p = 0,47, figure 1b), and separately in children and adults.
Conclusions
Incidence of IFD before allo-HSCT was 12,8%. Incidence of IFD after allo-HSCT was 17,6%. Despite the high incidence IFD before or after allo-HSCT didn’t influence the outcome in children and adults with Hodgkin lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3620 - Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours
Presenter: Wolfgang Wick
Session: Poster Display session 1
Resources:
Abstract
5465 - Proof of concept clinical study by US-guided intratumor injection of VCN-01, an oncolytic adenovirus expressing hyaluronidase in patients with pancreatic cancer
Presenter: Manuel Hidalgo
Session: Poster Display session 1
Resources:
Abstract
2555 - A Phase 1a/b first-in-human, open-label, dose-escalation, safety, PK and PD study of TP-0903 in solid tumors
Presenter: John Sarantopoulos
Session: Poster Display session 1
Resources:
Abstract
3533 - First in human phase 1/2a study of PEN-866, a Heat Shock Protein 90 (HSP90) ligand – SN38 conjugate for patients with advanced solid tumors: Phase 1 results
Presenter: Johanna Bendell
Session: Poster Display session 1
Resources:
Abstract
4114 - A Phase I Open-Label, Non-Randomized Study of Recombinant Super-Compound Interferon (rSIFN-co) In Patients with Advanced Solid Tumors
Presenter: Amanda Seet
Session: Poster Display session 1
Resources:
Abstract
2537 - Evaluation of Pharmacodynamic (PD) Biomarkers in Advanced Cancer Patients Treated with Oxidative Phosphorylation (OXPHOS) Inhibitor, OPC-317 (OPC)
Presenter: Jie Qing Eu
Session: Poster Display session 1
Resources:
Abstract
5764 - Pharmacokinetic (PK) assessment of BT1718: A phase 1/2a study of BT1718, a first in class Bicycle Toxin Conjugate (BTC), in patients (pts) with advanced solid tumours
Presenter: Natalie Cook
Session: Poster Display session 1
Resources:
Abstract
2683 - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumors.
Presenter: Wael Harb
Session: Poster Display session 1
Resources:
Abstract
3609 - Interim Results from Trial of SL-801, a Novel XPO-1 Inhibitor, in Patients with Advanced Solid Tumors
Presenter: Judy Wang
Session: Poster Display session 1
Resources:
Abstract
3485 - Phase 1 Trial of Fruquintinib in Patients with Advanced Solid Tumors: Results of the Dose Escalation Phase
Presenter: Andrea Wang-Gillam
Session: Poster Display session 1
Resources:
Abstract